CIK 0000014272
- Large accelerated filer
BRISTOL MYERS SQUIBB CO
Sign in to watch- Ticker
- BMY
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 220790350
- Phone
- +1 609-252-4621
- Business address
- ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NJ, 08543
Securities
- BMY Bristol-Myers Squibb Company Common Stock NYSE
- CELG-RI Rights NYSE
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $677,826
- in 3 filings
Net −$677,826. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-02-01 | Storch Gerald L Director | Grant or award · Deferred Share Units | +3,054.17 | $62.21 | $190K | 63,156.79 |
| 2021-02-01 | Paliwal Dinesh C Director | Grant or award · Deferred Share Units | +3,054.17 | $62.21 | $190K | 39,887.3 |
| 2021-02-01 | Rice Derica W Director | Grant or award · Deferred Share Units | +3,054.17 | $62.21 | $190K | 4,999.56 |
| 2021-02-01 | Samuels Theodore R. II Director | Grant or award · Deferred Share Units | +3,054.17 | $62.21 | $190K | 24,644.82 |
| 2021-02-01 | BONNEY MICHAEL W Director | Grant or award · Deferred Share Units | +3,054.17 | $62.21 | $190K | 8,564.74 |
| 2020-12-31 | VESSEY RUPERT EVP, Research & Early Dev. | Exercise or conversion | +25,866 | 68,074 | ||
| 2020-12-31 | VESSEY RUPERT EVP, Research & Early Dev. | Shares withheld for taxes | −13,257 | $62.03 | $822K | 54,817 |
| 2020-12-31 | VESSEY RUPERT EVP, Research & Early Dev. | Exercise or conversion · Restricted Stock Units | −25,866 | 0 | ||
| 2020-12-31 | Elkins David V EVP, Chief Financial Officer | Exercise or conversion | +20,624 | 79,111 | ||
| 2020-12-31 | Elkins David V EVP, Chief Financial Officer | Shares withheld for taxes | −11,931 | $62.03 | $740K | 67,180 |
| 2020-12-31 | Elkins David V EVP, Chief Financial Officer | Exercise or conversion · Restricted Stock Units | −20,624 | 0 | ||
| 2020-12-31 | AHMED NADIM EVP and President, Hematology | Exercise or conversion | +14,946 | 46,549 | ||
| 2020-12-31 | AHMED NADIM EVP and President, Hematology | Shares withheld for taxes | −7,660 | $62.03 | $475K | 38,889 |
| 2020-12-31 | AHMED NADIM EVP and President, Hematology | Exercise or conversion · Restricted Stock Units | −14,946 | 0 | ||
| 2020-12-31 | YALE PHYLLIS R Director | Grant or award · Deferred Share Units | +463.49 | $62.03 | $29K | 5,909.07 |
| 2020-12-31 | Vousden Karen H Director | Grant or award · Deferred Share Units | +156.17 | $62.03 | $10K | 14,609.85 |
| 2020-12-31 | Storch Gerald L Director | Grant or award · Deferred Share Units | +564.24 | $62.03 | $35K | 59,632.91 |
| 2020-12-31 | Samuels Theodore R. II Director | Grant or award · Deferred Share Units | +523.94 | $62.03 | $32K | 21,421.91 |
| 2020-12-31 | Rice Derica W Director | Grant or award · Deferred Share Units | +463.49 | $62.03 | $29K | 1,930.19 |
| 2020-12-31 | Price Paula A Director | Grant or award · Deferred Share Units | +115.87 | $62.03 | $7K | 1,469.67 |
Page 85 of 90 · 1,795 trades